FluroTech Receives Good Manufacturing Practice Validation of the CompleTest(TM) Cannabinoid Assays for THCa and CBDa

FluroTech (TSXV:TEST), (“FluroTech” or the “Company”), is pleased to report that preliminary Good Manufacturing Practice (“GMP”) validation testing, done by the Drug Development and Innovation Center at the University of Alberta, of the CompleTest™ cannabinoid assays for THCa and CBDa were recorded at less than 2% difference when compared to the industry quality control standard High Performance Liquid Chromatography (“HPLC”) technology.

HPLC analytic equipment is considered highly technical to operate and reasonably expensive to purchase with measurement results that are relatively slow. The use of the CompleTest™ provides a tremendous opportunity for cultivators to benefit from FluroTech’s technology providing ease of use, rapid measurement, high accuracy and low operating cost.

“This is a tool that no modern medical cannabis cultivator can go without. It takes all the guess work out of crop production,” stated, Dr. MacMillan, Director of Scientific Research and Business Development.

FluroTech’s technology provides an evidence-based solution for making critical operational decisions related to chemotypic plant screening and selection, breeding or determining the optimal time to harvest crops to maximize cannabinoid concentrations.

About CompleTest™

CompleTest™ is FluroTech’s flagship brand and product line. CompleTest™ is a portable, cost-effective, state-of-the-art cannabis testing device, able to provide quick, accurate and consistent testing results. It is designed for cultivators, dispensaries and anyone with a vested interest in consumer safety to test the quality and safety of their cannabis products and to optimize potency yield.

About FluroTech (TSXV: TEST)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary in conjunction with the University of Alberta, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com and watch our video.

Contact Information

FluroTech Ltd.
Alistair Ross Technology Centre
Suite 111, 3553-31 Street NW
Calgary, AB T2L 2K7
info@flurotech.com

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com

Prit Singh
IR — Thesis Capital Inc.
905.510.7636
psingh@thesiscapital.ca
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/5928/38892_fllogo.jpg

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the future performance of the Company.

The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the medical cannabis industry in general. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Click here to connect with FluroTech (TSXV:TEST) for an Investor Presentation. 

Source: www.newsfilecorp.com